Patent application number | Description | Published |
20110150923 | MUCOSAL MENINGOCOCCAL VACCINES - The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of | 06-23-2011 |
20130224245 | CONCENTRATION OF VACCINE ANTIGENS WITHOUT LYOPHILIZATION - An antigen concentration procedure does not involve lyophilisation of a bulk antigen before its final formulation and/or delivery. Thus a process for preparing a vaccine comprises steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen, to provide a concentrated antigen, and (ii) formulating a vaccine from the concentrated antigen. The concentrated antigen is not lyophilised between or during steps (i) and (ii). The invention is particularly useful for preparing solid vaccine forms. | 08-29-2013 |
20130236492 | ADJUVANTED FORMULATIONS OF BOOSTER VACCINES - The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response. | 09-12-2013 |
20130243841 | CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION - A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens. | 09-19-2013 |
20140112950 | COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT - Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant. | 04-24-2014 |
20140363461 | ADJUVANTED FORMULATIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The efficacy of | 12-11-2014 |
20150125486 | ADJUVANTED FORMULATIONS OF PEDIATRIC ANTIGENS - An immunogenic composition comprising a diphtheria toxoid, a tetanus toxoid, a pertussis toxoid, an aluminium salt adjuvant, and a TLR4 agonist. Preferably, the TLR4 agonist and/or at least one of the toxoids is/are adsorbed to the aluminium salt adjuvant. | 05-07-2015 |
20150190493 | COMBINATION VACCINES WITH SEROGROUP B MENINGOCOCCUS AND D/T/P - Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines. | 07-09-2015 |